SignalCorporate
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Q3 loss reported but revenue exceeded estimates, a positive earnings surprise.
Context
What happened: Travere Therapeutics ($TVTX) reported a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25, while revenue topped estimates.
Key numbers: Loss of $0.55 per share vs expected $0.25 loss; earnings surprise of -120.00%; revenue of $224.56 million vs estimate, a 16.64% beat; year-ago revenue $164.86 million; shares up about 31.9% year to
Why it matters: The estimate revisions trend ahead of the release was unfavorable, translating into a Zacks Rank #5 (Strong Sell), and the shares are expected to underperform the market in the near future.
Market: +4.0% today ($0.44), -72.3% YTD, 0.6x vol — as of 23:46 UTC
What changed
Travere Therapeutics ($TVTX) reported a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25, while revenue topped estimates.
Why it matters
The estimate revisions trend ahead of the release was unfavorable, translating into a Zacks Rank #5 (Strong Sell), and the shares are expected to underperform the market in the near future.
Market: +4.0% today ($0.44), -72.3% YTD, 0.6x vol — as of 23:46 UTC